The Food and Drug Administration has approved Pluvicto for men whose metastatic prostate cancer still responds to hormone therapy, a change that Novartis says nearly doubles the number of patients eligible for the treatment. The decision, announced July 31, allows the radioligand therapy to be used in combination with an androgen receptor pathway inhibitor much earlier in the disease than before.
For patients, the practical question that follows is not whether the drug works. It is whether they can get to a place that is legally permitted to give it.
Pluvicto is not a pill or a standard infusion. It is a radioactive medicine with a half-life measured in days, manufactured to order and shipped to a specific site for a specific patient. It can only be administered at facilities holding the required radioactive materials license with appropriately trained nuclear medicine staff. That constraint has shaped who receives this class of therapy since the drug was first approved in 2022, and expanding eligibility does not by itself expand the map of places that can deliver it.
An Approval That Widens the Eligible Population Sharply
The expansion covers PSMA-positive metastatic androgen pathway modulation-naive or sensitive prostate cancer, the disease stage previously called metastatic hormone-sensitive prostate cancer. Pluvicto was already approved for the later, castration-resistant stage.
The approval rests on the Phase III PSMAddition trial, which found that adding Pluvicto to standard of care reduced the risk of progression or death by 28% at primary analysis and 33% at a later updated analysis. Novartis reported an overall survival trend favoring the combination, with a hazard ratio of 0.80 and a confidence interval crossing 1.0, meaning survival data are not yet mature.
That distinction matters. The approval is based primarily on delayed disease progression, not on a confirmed survival benefit. Final overall survival analysis is still pending.
Dr. Michael Morris, prostate cancer section head in genitourinary oncology at Memorial Sloan Kettering Cancer Center and a US principal investigator on the trial, framed the change in terms of options rather than cures. "Having a radioligand therapy available at this stage meaningfully expands the options," he said in the company's announcement. His role as a trial investigator should be read alongside the comment.
Safety in the trial was consistent with earlier studies. Grade 3 or higher adverse events occurred in 50.7% of patients receiving Pluvicto plus standard of care, compared with 43.0% receiving standard of care alone. The most common side effects across all grades were dry mouth, fatigue, nausea, hot flush and anemia.
Getting In Requires a PSMA PET Scan First
Before any patient receives Pluvicto, a PSMA PET scan using an FDA-approved imaging agent must confirm that the tumor expresses enough PSMA. That scan is its own access hurdle, since PET imaging with these agents is also concentrated at larger centers and requires prior authorization from most insurers.
The PSMA biomarker is present in more than 80% of prostate cancer patients, according to figures cited in the company release, so most men who are scanned will qualify on biology. The bottleneck is logistical rather than biological.
A patient in a metropolitan area with an academic cancer center may complete imaging and start treatment within weeks. A patient several hours from the nearest licensed nuclear medicine facility faces a different calculation, because the dosing schedule requires returning to that same site repeatedly. The regimen is one dose every six weeks for up to six doses, which means a course can span roughly 30 weeks of scheduled travel.
The Manufacturing Claim Deserves Careful Reading
Novartis states that it has five US radioligand therapy manufacturing sites operational or under construction, and that it can deliver Pluvicto to US treatment sites within five days. Both figures come from the company, not from a regulator, and the release does not break out how many of the five are producing doses today versus still being built.
Publicly reported context fills in part of the picture. The company has previously announced FDA clearance for commercial manufacturing at facilities in Millburn, New Jersey, and Indianapolis, and trade press reported the opening of a Carlsbad, California, site in April 2026 aimed at serving the western United States, Alaska and Hawaii. Novartis has also announced construction of isotope production capacity in Indianapolis.
Proximity is not a marketing detail for this product category. Each dose is made for one named patient, and the clock starts at production. A supply network that works reliably for a treatment given to a few thousand men becomes a harder engineering problem when eligibility roughly doubles, and whether it holds is a question that will be answered by delivery performance over the next year rather than by a press release.
Manufacturing capacity also is not the same thing as administration capacity. Even with unconstrained supply, the number of sites licensed and staffed to handle a radiopharmaceutical determines how many patients can actually be treated.
Radiation Precautions Reach into the Household
The part of this treatment that families often do not anticipate is what happens after the patient goes home.
Because Pluvicto involves radioactivity, the prescribing information sets out contact limits following each dose. Patients are advised to limit close contact within three feet with household members for two days, and with children and pregnant women for seven days. Sleeping arrangements are separated for three days from household contacts, seven days from children and 15 days from pregnant women. Sexual activity is avoided for seven days. Patients are told to drink plenty of water and urinate frequently in the hours after administration.
For a household with a grandchild visiting, a pregnant daughter-in-law, or a small apartment with one bedroom, those instructions require planning. They are also a reason the treatment cannot be arranged casually around a work schedule.
Serious risks listed include low blood cell counts and kidney problems, and the therapy may cause temporary or permanent infertility. Patients should report new or worsening tiredness, pallor, shortness of breath, easy bruising or bleeding, frequent infections or new urinary symptoms to their care team promptly. Nobody should start, stop or change any cancer treatment based on a news article. These decisions belong with a treating oncologist.
Cost and Coverage Questions Worth Raising Early
Radiopharmaceuticals are expensive, and the billing pathway differs from ordinary chemotherapy because the treatment is delivered in a hospital nuclear medicine setting. Patients should ask their care team three things before the first dose: whether the PSMA PET scan and the therapy require separate prior authorizations, whether the administering site is in network, and what the out-of-pocket estimate looks like per dose rather than per course.
Novartis operates a patient support program that assists with coverage questions and financial assistance screening, reachable at 1-844-638-7222 or through its support page. Program eligibility rules are set by the manufacturer.
For patients in rural areas, the practical costs also include travel, lodging and lost work across a treatment course that may run seven months. Some cancer centers have travel assistance funds, and hospital social workers are the fastest route to finding them.
What happens next is largely a distribution story. The measurable questions are how many treatment centers add radioligand capability, whether delivery timelines hold as volume rises, and whether the final overall survival analysis from PSMAddition confirms a benefit beyond delayed progression. MedicalDaily will report the survival results and any change in treatment-site availability.
Frequently Asked Questions
What changed? The FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic prostate cancer that still responds to hormone therapy, an earlier stage than its prior approval.
Who is now eligible? Adults with PSMA-positive metastatic disease confirmed by a PSMA PET scan. Novartis says the expansion nearly doubles the eligible population.
Where can it be given? Only at facilities licensed to handle radioactive materials with trained nuclear medicine staff. Ask your oncologist for the nearest administering site.
How many treatments are involved? One dose every six weeks for up to six doses, which can span roughly 30 weeks including scheduled visits.
Does it help people live longer? The approval was based mainly on delayed disease progression. An overall survival trend favored the combination but is not yet statistically mature.
Are there precautions at home? Yes. The label sets limits on close contact and sleeping arrangements with household members, children and pregnant women for several days after each dose.
What are the main side effects? Dry mouth, fatigue, nausea, hot flush and anemia are most common. Low blood cell counts and kidney problems are among the serious risks listed.
